H.C. Wainwright initiated coverage of Lexicon with a Buy rating and $10 price target. The commercial-stage biotechnology company is focused on developing orally delivered small molecule inhibitors derived from its internal Genome5000 technology, notes the analyst, who points out that Lexicon has identified over 100 proteins with significant therapeutic potential to date and is currently advancing three candidates in its pipeline. Sotagliflozin, commercialized in the U.S. for heart failure as INPEFA, commercialized in Europe for type 1 diabetes as Zynquista and in late-stage clinical development for T1D, is “a pipeline on its own,” the analyst added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
- Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
- Lexicon management to meet with Piper Sandler
- Lexicon announces new post-hoc analysis of data on INPEFA
- New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction